Warner Chilcott Ltd: Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2008-01-08

Order Online Now

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Warner Chilcott is a specialty pharmaceutical company focused on two therapeutic segments: women's health and dermatology. The company's predecessor company was purchased by a private equity consortium in January 2005. The company has a strong portfolio of marketed and pipeline products.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    Warner Chilcott is engaged in developing, manufacturing ,marketing and selling branded prescription products in women's healthcare and dermatology. Women's healthcare related products include Loestrin 24 FE, Ovcon 35 and Ovcon 50, Femcon FE, Estrostep FE, Femhrt and Estrace Cream and Dermatology related products include Taclonex, Dovonex and Doryx.

    The company's total revenues increased at a CAGR of 34% during 2002-2006, from $235 million to $754 million. The company's biggest contributor to revenue growth during 2002-2006 was product sales which recorded revenues of $752 million for the fiscal year 2006. The major contributors were Dovonex, Estrostep FE, Taclonex,Femhrt, and Loestrin 24 FE.

    The company's biggest contributor to sales growth out to 2010 will be the sales of Loestrin 24 FE, indicated for the prevention of pregnancy in women. Revenues from Loestrin are expected to increase at a CAGR of 59%, from $44 million in 2006 to $284 million in 2010. This represents an absolute growth of +$240 million


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: Warner Chilcott warner chilcott loestrin 24 ltd wc3026 competitors company pipeline card

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.